Selatogrel
Selatogrel is a novel antiplatelet medication under investigation for its potential use in preventing and treating thrombosis, a condition characterized by the formation of blood clots within blood vessels, which can lead to myocardial infarction (heart attack) or stroke. Selatogrel works by inhibiting the P2Y12 receptor on the surface of platelets, which plays a crucial role in platelet activation and aggregation, a key step in the formation of blood clots.
Mechanism of Action[edit | edit source]
Selatogrel inhibits the P2Y12 receptor, a G protein-coupled receptor on the platelet surface that is involved in platelet activation. When platelets are activated, they change shape, release granules that attract and activate more platelets, and become sticky, aggregating together to form a clot. By blocking the P2Y12 receptor, Selatogrel prevents platelet activation and aggregation, thereby reducing the risk of clot formation.
Clinical Trials[edit | edit source]
Selatogrel has been evaluated in various clinical trials for its efficacy and safety in the prevention and treatment of arterial thrombosis. These studies have explored its use in different populations, including patients with a history of myocardial infarction and those undergoing percutaneous coronary intervention (PCI), a common procedure to open blocked coronary arteries.
Potential Benefits and Risks[edit | edit source]
The potential benefits of Selatogrel include its rapid onset of action and its ability to significantly reduce the risk of thrombotic events, which can be life-threatening. However, as with all antiplatelet agents, there is a risk of bleeding, since inhibiting platelet function can impair the body's ability to form clots necessary to stop bleeding.
Current Status[edit | edit source]
As of the last update, Selatogrel is not yet approved for clinical use and is still under investigation in clinical trials. Its development and potential approval will depend on the outcomes of these trials, demonstrating a favorable balance of efficacy in preventing thrombotic events against the risk of bleeding.
See Also[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
